Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.46 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.43 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL387995 | 0.86 | GPR119 (0.47) | GPR119TBK1LIMK2TGFBR1KDM4E | |
| SCHEMBL391649 | 0.83 | GPR119 (0.46) | GPR119TBK1LIMK2TGFBR1KDM4E | |
| SCHEMBL390308 | 0.82 | TBK1 (0.46) | GPR119TBK1LIMK2TGFBR1 | |
| SCHEMBL1070548 | 0.81 | TBK1 (0.44) | GPR119TBK1LIMK2TGFBR1KDM4E | |
| SCHEMBL391067 | 0.80 | GPR119 (0.47) | GPR119TBK1CYP3A4CYP2C9 | |
| SCHEMBL389112 | 0.80 | TBK1 (0.48) | GPR119TBK1CYP3A4CYP2C9 | |
| SCHEMBL390725 | 0.80 | GPR119 (0.54) | GPR119CYP3A4CYP2C9 | |
| SCHEMBL389556 | 0.80 | CYP2C9 (0.57) | GPR119CYP3A4CYP2C9 | |
| SCHEMBL391170 | 0.80 | GPR119 (0.48) | GPR119TBK1LIMK2CYP3A4CYP2C9 | |
| SCHEMBL391077 | 0.80 | TBK1 (0.47) | GPR119TBK1LIMK2TGFBR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2116235-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | Arena Pharmaceuticals, Inc. (US) | 2009-11-11 | — | — | EP | disclosed |